Moneycontrol
    Moneycontrol PRO
    LAMF
    LAMF

    At Moneycontrol, the Results page helps you effectively track corporate announcements and results for various listed companies across both India and abroad. With our Results page, you can keep abreast with an updated, comprehensive view of all the profit/loss statements, company spendings, AGM outcomes, and quarterly and annual results from all these listed companies. Additionally, Moneycontrol also regularly tracks international MNCs listed on NASDAQ and Asian bourses, including popular companies like Apple, Google, Alibaba. Apart from finding solid copies of company results, stock movements consequent to these company results, expectations, and analytical post results copies, you will also find copies and articles detailing the earnings, impact, and all major announcements made to media/exchanges by these companies, so that you do not miss anything. We also provide you with concrete data points to help you spot profitable trades, stock build-ups, and bulk deals. At Moneycontrol, we also cover analysts/investors meetings; scrutinise results and data and BSE/NSE reports or news. The copies are not just full of information and data, but are also adequately supplemented with expert views, investor opinions, extensive interviews, videos, and a huge variety of explainers, analyses, and informative slideshows to help you gauge the market and make investment decisions in the best possible manner. More

    Jump to

    • Dr. Lal PathLabs Q2 PAT seen up 28.4% YoY to Rs 112 cr: Prabhudas Lilladher

    • Dr. Lal PathLabs Q3 PAT seen up 27.4% YoY to Rs. 54.1 cr: Prabhudas Lilladher

    • Dr Lal Pathlabs Q2 PAT seen up 48.8% YoY to Rs. 84.8 cr: Kotak

    • Dr Lal Pathlabs Q1 PAT seen up 17.6% YoY to Rs. 58.1 cr: Kotak

    • Dr. Lal PathLabs Q1 PAT seen up 5.5% YoY to Rs. 52.1 cr: Prabhudas Lilladher

    • Dr Lal Pathlabs Q4 PAT seen up 28.3% YoY to Rs. 51.4 cr: Kotak

    • Dr. Lal Pathlabs Q4 PAT seen up 26.2% YoY to Rs. 50.6 cr: Prabhudas Lilladher

    • Brokerages remain mixed on Dr Lal PathLabs Q2 show; Citi maintains buy rating

    • Dr Lal Pathlabs Q1 PAT seen up 13.3% YoY to Rs. 50.1 cr: Kotak

    • Dr. Lal Pathlabs Q4 PAT seen up 19.7% YoY to Rs 37.5 cr: Edelweiss

    • Competitive pricing leads to higher volume growth, says Dr Lal Pathlabs

    • Expect 26-27% margins for full year; Q3, Q4 to be good on low base: Dr Lal PathLabs

    • Dr Lal Pathlabs Q2 PAT may dip 0.9% YoY to Rs. 52 cr: Kotak

    • Acquisition in Bangladesh is minor, won't impact FY18 numbers: Dr Lal Pathlab

    • Volume performance to improve going ahead: Dr Lal PathLabs

    • Dr. Lal Pathlabs Q4 PAT seen up 30.8% to Rs 40.4 cr: ICICI Securities

    • Dr Lal PathLabs to start Kolkata operations next year

    • Dr. Lal Pathlab Q3 PAT may dip 20% to Rs 42 cr: ICICI Securities

    • Dr Lal PathLabs sees margins declining 200-300 bps in 2-3 yrs

    • Dr Lal PathLabs expects good volumes in Q2

    • Confident of beating sector growth of 16-17%: Dr Lal PathLabs

    • May outperform industry's 17% FY17 growth rate forecast: Dr Lal

    • Expect margins to be in range of 25-26%: Dr Lal Pathlabs

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347